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ABSTRACT
Abbass,
Aya Background:Palonosetron is a 5HT3 receptor antagonist which is used to
Mohammed , email: prevent postoperative nausea and vomiting (PONV).Design:Prospective
aya_elnagger@yahoo.com Randomized Double Blinded Controlled Clinical Trail.
Patients and methods:A total of 200 female patients of ASA physical
status class I and II scheduled for gynecological laparoscopic surgery were
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randomly allocated into four groups: Control group (group C) received 5
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ml saline; Palonosetron group (group P) received 0.075 mg palonosetron;
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Dexamethasone group (group D) received 8 mg dexamethasone and
combined Palonosetron/ Dexamethasone (group P/D) group received a
combination of 0.075 palonosetron and 8 mg dexamethasone. Studied
drugs were given intravenously(iv) immediately before induction of
anaesthesia. Anaesthesia was induced with propofol and fentanyl and
maintained with isoflurane/oxygen/air. Diclofenac sodium was given
intramuscularly for postoperative analgesia. Metoclopramide was used as
rescue antiemetic. Overall incidence, severities of PONV, number of
patients who needed rescue antiemetic and side effects of the used drugs
were recorded during 1st 24 hours postoperatively.
Results:The overall incidences, severities of PONV and the number of
patients who needed rescue antiemetic in group P, D and P/D were
significantly lower than that in group C. Group P and P/D were
comparable and significantly lower than that in group D. Side effects of
the used drugs were minimal and comparable.
Conclusion:Palonosetron
and
combined
palonosetron
with
dexamethasone were comparable and superior to dexamethasone in
reducing the incidence and severity of PONV and need to rescue
antiemetic in gynecological laparoscopic surgery.
Keywords:
Palonosetron, Dexamethasone, Postoperative nausea and vomiting,
laparoscopic surgery.

P

INTRODUCTION
ostoperative nausea and vomiting (PONV)
is one of most frequent side effects after
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anaesthesia. It occurs in 30% of unselected
patients and up to 70% of “high-risk” patients
(1).
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The risk factors are female gender, previous
history of PONV and motion sickness, nonsmoking status, volatile anaesthetic agents,
N2O,
excess
opioids,
intra-abdominal,
gynecological, laparoscopic, middle ear and
ophthalmic surgeries (2).
In general, combination therapy is superior to
monotherapy for PONV prophylaxis (3).
Palonosetron is a 5-HT 3 antagonist approved
for the prevention and treatment of PONV. It
has been described as a “second generation” 5HT 3 antagonist since it has greater receptorbinding properties, which results in a much
longer half-life than the previously described
5HT3 antagonists (4).
Dexamethasone is a synthetic glucocorticoid
used extensively in both adults and children (5).
Its action in prevention of PONV is through
inhibiting prostaglandin synthesis, decreasing
5HT levels in the nervous system (6).
The aim of this work was to compare between
the
efficacies
of
pre-induction
IV
administration of placebo, palonosetron,
dexamethasone
and
combination
of
palonosetron
with
dexamethasone
for
prevention of PONV after laparoscopic
gynecological surgeries to find out which one
has the better outcome and least side effects.
Patient and methods:
After obtaining approval from Institutional
Review Board (IRB) and written informed
consent from each patient, this prospective
double blinded randomized controlled clinical
study was carried out at the Zagazig University
Hospitals from August 2017 to August 2018.
The work has been carried out in accordance
with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for
studies involving humans.
A total of 200 female patients with inclusion
criteria: of ASA physical status (PS) class I
and II aged between 20-60 years with body
mass index(BMI) not more than 35 kg m2,,
,Non-smokers, with or without history of
previous PONV, undergoing laparoscopic
gynecological surgeries were enrolled in this
study.
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Exclusion criteria
were: history of
hypersensitivity
to
any
tested
drug,
contraindication to use corticosteroids, patients
on (antidepressants, calcium channel blockers,
opioids, steroids and antiemetics) before
surgery.
The patients were randomly allocated into four
groups by computer generated random number
table which was sealed in opaque envelope.
- Control group (Group C) received 5 ml of
normal saline as placebo.
- Palonosetron group (Group P): received
0.075 mg of palonosetron (1.5 ml) [Emegrand,
Grand pharma] diluted to 5 ml with normal
saline.
- Dexamethasone group (Group D)
received 8 mg dexamethason (2 ml)
[dexamethason,
Medical
Union
Pharmaceuticals] diluted to 5 ml with normal
saline.
Combined
palonosetron
with
Dexamethasone group (Group P/D) received
both 0.075 mg palonosetron plus 8mg
dexamethasone diluted to 5 ml with normal
saline.
For blindness, one of the authors was
responsible for giving the tested drug and other
one unaware of the given drug was responsible
for data collection. Also, patients were blind to
group assignment.
All tested drugs were given iv immediately
before induction of general anaesthesia.
General anaesthesia was induced by iv injection
of 1.5 mg/kg propofol and 1ug/kg fentanyl.
Tracheal intubation was facilitated by iv
injection of 0.8 mg/kg rocuronium. Nasogastric
tube was introduced after induction.
Anaesthesia was maintained with 1–1.5%
isoflurane
in
oxygen/air
(50%:50%).
Ventilation was mechanically controlled
throughout surgery. Patients were placed in the
reverse Trendelenburg position and abdomen
was insufflated with CO2 to a maximum of 17
mmHg.
At the end of surgery, the insufflated CO2 was
removed and suction of gastric content was
performed. The residual effect of rocuronium
was reversed by iv administration of a mixture
295 | P a g e
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of 0.05mg/kg neostigmine and 0.01mg/kg of
atropine sulphate.
After extubation, all patients were shifted to
post anaesthetic care unit and monitored for
heart rate, blood pressure, SpO2 for first 24
hours postoperatively, diclofenac sodium (1.5
mg/kg) was given intramuscularly for
analgesia.
Data collection:
Pre operative:
- The heart rate and mean arterial blood
pressure values were recorded immediately
before tested drug administration (Base line
values).
Intra operative:
- Heart rate and the mean arterial blood
pressure were recorded at 2 min, 5 min, 10 min,
20 min and 30 min after tested drug
administration.
- Durations of general anaesthesia and surgery
were recorded.
Post operative:
Through out the 1st 24 hours postoperatively,
the following were recorded:
- The overall incidences and the various
severities` levels of PONV (Score 0- no nausea
, Score 1- nausea only, Score 2- nausea with
retching , Score 3- vomiting).
- Number of patients (%) who received rescue
antiemetic.
- The incidences of the various side effects as
bradycardia, hypotension, dizziness, diarrhea
and flushing of the face were recorded.
Sample size calculation:
According to the research work of Bala et al.
(7).
the incidence of no PONV with
palonosterion/dexamethason was 74% and the
incidence of no PONV with palonosterion alone
was 50% and at 80% power and 95%
Confidence Interval , the calculated sample
size by using Epi Info version 6 program was
184 adult female patients. For compensation of
the dropped cases 200 adult female patients
with inclusion criteria was selected for this
study and was randomly allocated into 4 equal
groups by computer generated random table.
Statistical analysis:
Aya A., et al
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Data were checked, entered, and analyzed using
SPSS version 20. Qualitative values were
represented as number and percentage and
quantitative continues values were represented
by mean ± SD. Chi square test (X2) was used
for statistical analysis of Qualitative values.
ANOVA or Kruskal Wallis test was used for
statistical analysis of Quantitative values. P
value <0.05 means significant differences and P
value < 0.001 means highly significant
difference.
RESULTS
Among the 200 patients who were eligible for
the study, a total of 10 patients refused to
participate and 6 patients were excluded due to
ineligibility. A total of 184 patients were
randomized to 4 groups (Fig. 1).
The demographic data (Age, BMI and ASA ps
classes ratio), surgery and anaesthesia durations
of the four tested groups were comparable
(Tab. 1).
Statistically, the overall incidences of PONV
in the patients of group P, group D and group
P/D were highly significant, significantly and
highly significant lower than that in group C
respectively (p1=0.000 ,p6=0.037, p4=0.000)
respectively . In group P, it was significantly
lower than that in group D (p2= 0.012) and
comparable with that in group P/D (p3=0.599).
In group P/D, it was highly significant lower
than that in group D (p5=0.001) (Tab. 2).
Statistically, the severity score of PONV in the
patients of group P, group D and group P/D
were highly significant, significantly and highly
significant less than that in group C
respectively (p1=0.000, p6=0.000,p4=0.001)
respectively. In group P, PONV severity score
was significantly less than that in patients of
group D (p2=0.011) and comparable with that in
patients of group P/D (p3=0.432) . In group P/D it
was highly significant less than that in patients of
group D (p5=0.012) (Tab.3).
Statistically, the number (%) of patients who
were in need to rescue antiemetics throughout
the first 24 h postoperatively in the patients of
group P, group D and group P/D were highly
significant lower than that in group C
(p1=0.000 , p6=0.000 , p4=0.001) respectively.
296 | P a g e
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In group P, it was significantly lower than that
in group D(p2=0.01) and comparable with that
in group P/D (p3=0.740). In group P/D, it was
highly significant lower than that in groupD
(p5=0.018) (Tab.3).
Statistically, heart rate and the mean arterial
blood pressure values at various times of

measurements in the four tested groups were
comparable. Clinically, heart rate and MAP in
group P/D was the highest followed by group D
than group P and lastly group C (Tab. 4 and 5).
The incidences of the various associated sideeffects in the four groups were minimal and
statistically comparable (Tab. 6).

Table (1): Demographic data (Age, BMI and ASA ps classes ratio), surgery and anaesthesia
durations of the four tested groups.
Group P
(n=46)
Mean±SD
28.6±5.88

Group D
(n=46)
Mean±SD
26.5±4.5

Group P/D
(n=46)
Mean±SD
28.8±6.7

F

P

Age (years).

Group C
(n= 46)
Mean±SD
26.5±4.8

2.397

0.07

BMI (kg/m2).

26.9±3.2

27.6±7.53

27.4±2.9

28.2±3.2

0.695

0.556

Surgery
duration
(min).
Anaesthesia duration
(min).

33.8±25.3

35.1±20.9

38.4±20.1

39.7±24.9

4.3

0.231

38.8±25.3

40.3±20.8

43.5±20.1

44.7±24.9

4.24

0.237

Ratio

X2

P

6/40

6.06

0.108

Ratio
Ratio

Ratio
8/38

ASA ps class I/ II
(Ratio).

10/36

5/41

Data are expressed as Mean  Standard Deviation (SD) or numbers.
Group C = Control group.
Group P= Palonosetron group.
Group D =Dexamethason group. Group PD=Palonosetron plus Dexamethasone group.
BMI = Body Mass Index.
ASA ps class=American Society of Anesthesiology physical status class.
F = one way ANOVA test.
K = Kruskall Wallis test (Non parametric data).
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Table ( 2 ): The overall incidence of PONV in the four tested groups.
Group C
(n=46)
N (%)
29 (63%)

Group P
(n=46)

Group D
(n=46)

N (%)
10 (21.7%)

N (%)
19 (46%)

PONV
Incidence

Group
P/D
( n=46)
N (%)
8 (17.4%)

x2

P

26.547

P<0.001**
P1=0.000**
P2=0.012*
P3=0.599
P4=0.000**
P5=0.001**
P6=0.037*

Data are expressed as number and percentage.
n =Group number.
N= number of patients who suffered from POVN in each group.
Group C = Control group.
Group P =Palonosetron group
Group D=Dexamethason group Group P/D=Combined palonosetron and Dexamethasone group.
P= Comparison among the four tested groups.
P1= Group P vs Group C.
P2= Group P vs Group D.
P3= Group P vs Group P/D.
P4 = Group P/D vs Group C.
P5= Group P/D vs Group D.
P6 =Group D vs Group C.
PONV= Postoperative Nausea and Vomiting.

Table (3): The severity Scores of PONV and numbers (%) of patients who were in need to rescue
antiemetic throughout the first 24 h postoperatively in the four tested groups.
PONV
Group C
Group P
Group D
Group P/D X2
P
severity
(n=46)
(n=46)
(n=46)
(n=46)
score
N (%)
N (%)
N (%)
N (%)
Score:
28.831 P= 0.001**
17 (37.0%)
38 (82.6%)
0
P1=0.000**
01 (21.7%) 36 (78.3%)
27 (58.7%)
6 (13.0%)
1
P2=0.011*
01 (26.0%)
7 (15.2%)
10 (21.7%)
1 ( 2.2%)
2
P3=0.432
7 (15.2%)
2 ( 4.3%)
5 (10.9%)
1 ( 2.2%)
3
P4=0.001*
1 ( 2.2%)
4 ( 8.7%)
P5=0.012**
P6=0.000**
01 (41.3%)
2 (6.5%)
9 (19.5%)
1 (4.3%)
26.993 P<0.001**
Number
P1=0.000**
(%)
of
P2=0.01*
patients
P3=0.740
who were
P4=0.001**
in need to
P5=0.018**
rescue anti
P6=0.000**
emetics.
Data are expressed as number and percentage. n = number of patients in the each group.
Group C = Control group.
Group P =Palonosetron group
Group D=Dexamethason group. Group P/D=Combined palonosetron and Dexamethasone group.
P= Comparison among the four tested groups.
P1= Group P vs Group C.
P2= Group P vs group D.
P3= Group P vs group P/D.
P4 = Group P/D vs group C.
P5= Group P/D vs Group D.
P6 =Group D vs Group C.
PONV= Postoperative Nausea and Vomiting.
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Table (4): The mean heart rate values (beats/min) at the various times of measurements of the
four tested groups.
Heart rate values
(min).

Immediately
before
tested
drug
administration
(Basal level).

- At various
times
after
tested
drug
administration:

Group C
(n=46)
Mean ± SD

Group P
Group D
(n=46)
(n=46)
Mean
± Mean ±SD
SD

GroupP/D
(n=46)
Mean ±SD

F

P

0.543
0.653
86.8±13.1

88.4±13.9

90.2±14.1
89.6±14.3

0.076
82.5±10.4
84.6±9.5

2.362
85.2±10.6

88.3±12.2

- 2 min.
- 5 min.

73.4±9.3

74.5±12.1

74.7±14.7

76.1±13.7

0.340

0.797

- 10 min.

70.6±10.7

72.7±15.1

74.5±10.3

73.4±14.2

1.864

0.137

- 20 min.

68.5±12.2

69.2±11.5

71.7±13.1

72±14.6

0.769

0.513

- 30 min.

69.1±10.1

70.7±11.9

70.9±11.4

71.5±13.4

0.252

0.860

HR for heart rate.
F for one way ANOVA.
Data are expressed as Mean  Standerd Deviation (SD)
n = number of patients in the each group.
Group C = Control group.
Group P =Palonosetron group.
Group D=Dexamethason group
Group P/D=Combined palonosetron and Dexamethasone
group.
P= Comparison among the four tested groups.
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Table (5): Mean arterial blood pressure values (mmHg) at the various times of measurements of
the four tested groups.
MAP
(mmHg).

values

Immediately
before tested drug
administration
(Basal level).
- At various times
after tested drug
administration
- 2 min.

Group C
(n=46)
Mean ± SD

Group P
(n=46)
Mean ± SD

Group D
(n=46)
Mean ± SD

Group P/D
(n=46)
Mean ± SD

F

P

2.518
0.060
94.6±12.1

88.6±10.9

91.8±93

89.6±12.4

85.4±12.8

87.4±13.8

89.2±9.8

0.231
84.4±10.7

- 5 min.

1.447

83.2±16.6

84.5±13.2

85.3±8.7

1.446

0.231

80.1±13.2
- 10 min.

79.7±12.8

82.2±8.7

82.1±13.1

82.2±12.8

0.492

0.688

- 20 min.

79.1±10.8

79.9±9.7

81.7±10.1

82.3±12.3

0.784

0.504

- 30 min.

77.2±9.9

77.6±10.1

79.1±9.5

79.3±7.8

0.425

0.735

Data are expressed as Mean  Standerd Deviation (SD). MAP =Mean arterial pressure.
F for one way ANOVA.
n = number of patients in the each group.
Group C = Control group.
Group P =Palonosetron group.
Group D=Dexamethason group.
Group P/D=Combined Palonosetron and Dexamethasone
group.
P= Comparison among the four tested groups.

Table (6): The incidences of the associated various side-effects.
Group C
Group P
Group D
(n=46)
(n=46)
(n=46)
N (%)
N (%)
N (%)
Bradycardia

Group P/D
(n=46)
N (%)

x2

P

3 (6.5%)

2 (4.3%)

1 (2.2%)

3.384

0.336

5 (10.9%)
Hypotension

3 ( 6.5%)

2 (4.3%)

1 (2.2%)

1 (2.2%)

0.68

0.876

Headache

0 (0.0%)

2 (4.3%)

0 (0.0%)

1 (2.2%)

3.7

0.292

Dizziness

0 (0.0%)

3 (6.5%)

0 (0.0%)

2 (4.3%)

5.5

0.136

Data are expressed as number and percentage.
n= number of patients in each group.
Group C = Control group.
Group P =Palonosetron group.
Group D=Dexamethason group.
Group P/D=Combined Palonosetron and Dexamethasone
group.
P= Comparison among the four tested groups.
P< 0.05 = non significant.
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DISCUSSION
The present study showed that, palonosetron,
dexamethasone and combined palonosetron
with dexamethason were effective in lowering
the incidence of PONV when used in female
patients undergoing laparoscopic surgery under
general anaesthesia. Also, this present study
showed that, the effect of palonosetron alone
was comparable with that of combined
palonosetron with dexamethasone and the
effect of each of them was superior to
dexamethasone in lowering the incidence of
PONV.
These results were in agreement with some
workers. Fujii and Itakura (8) reported that, the
prophylactic therapy with 8 mg dexamethasone

Aya A., et al
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was effective in reducing PONV after
laparoscopic cholecycstectomy.
Blitz, et al. (9), Park, et al. (10), Kim, et al. (11)
and Srivastava, et al. (12) reported that,
palonosetron alone and combined palonosetron
with dexamethason were comparable in
lowering the incidence of PONV when used in
patients undergoing elective laparoscopic
surgery under general anaesthesia.
In contrast, the results of the present study
were in disagreement with other workers`
results. Bhattarai, et al., (13) reported that, the
combined ondanoserton with dexamethason
was superior to ondanosetron alone in lowering
the incidence of PONV when both were used in
patients undergoing laparascopic surgeries.
D`souza, et
al.
(14) reported that
301 | P a g e
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dexamethasone was more effective in
decreasing PONV than ondanosetron in females
undergoing laparoscopic gynecological surgery.
Bala, et al. (7) reported that, combined
palonosetron with dexamethason was superior
to palonosetron alone in lowering the incidence
of PONV when both were used in laparoscopic
choleycystectomy. Kim, et al.,(11) found that,
palonosetron
and
dexamethasone
were
comparable in lowering the incidence and
severity of PONV in patients undergoing
thyroid surgery under general anaesthesia .
This controversy between the present study
findings and the findings of the other workers
was attributed to some factors as the use of
premedications which have some antiemetic
effects, the use of different anaesthetic drugs
for maintenance of general anaesthesia and the
use of different types of antiemetic and the
administration of the antiemetics at different
times. Bhattarai, et al (13) used midazolam and
diazepam for premedication which have some
antiemetic effects but no premedication was
used in the present study also they used
ondanosetron for prevention of PONV 5 min
before induction of anaesthesia ,whereas in the
present study, palonosetron was used for
prevention of PONV immediately before
induction of general anaesthesia. D`souza, et
al., (14) used oxygen (40%), nitrous oxide
(60%), sevoflurane (2%) for maintenance of
general anaesthesia and ondanosetron and
dexamethasone for prevention of PONV 5 min
before induction of anaesthesia ,but in the
present study, a mixture of isoflurane and
oxygen/air (50%:50%) was used for
maintenance of general anaesthesia and
palonosetron, dexamethasone and their
combination were used for prevention of PONV
immediately before induction of general
anaesthesia. Bala, et al., (7) used mixture of
isoflurane and nitrous oxide for maintenance of
general anaesthesia and palonosetron and
combined palonosetron/ dexamethasone for
prevention of PONV immediatley before
induction of anaesthesia ,but in the present
study, a mixture of isoflurane and oxygen/air
was used for maintenance of general
Aya A., et al
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anaesthesia and palonosetron , dexamethasone
and their combination was used for prevention
of PONV immediately before induction of
general anaesthesia.
The present study showed that, the effect of
palonosetron alone was comparable with that of
combined palonosetron with dexamethasone
and the effect of each of them was superior to
dexamethasone in lowering severity of PONV.
These present study findings were in agreement
with some workers. Ghosh et al. (15) found
that, palonosetron alone was comparable with
combined palonosetron with dexamethason in
lowering the severity of PONV when used in
patients
scheduled
for
laparoscopic
choleycystectomy under general anesthesia
.Song and lee (16) reported that, ramosetron
(the 5HT3 antagonist) was superior to
dexamethasone, in lowering the severity of
PONV in females undergoing thyroid surgery
.Bala et al. (7) reported that there was no
significant difference in the severity of PONV
between
palonosetron
and
palonosetron/dexamethasone groups in patients
undergoing laparoscopic cholecystectomy .
The detected superiority of palonosetron over
dexamethasone in lowering the severity of
PONV in the present study was attributed to the
longer period of palonosetron efficacy than
dexamethasone as it has a strong affinity for
5HT3 receptor allosteric site (17).
In contrast to these present study finding, Kim,
et al. (11) reported that, palonosetron was
comparable with dexamethasone in lowering
the severity of PONV in patients undergoing
thyroid surgery under general anaesthesia and
receiving opioid based patient controlled
analgesia (PCA) for post operative analgesia .
The controversy between the present study
finding and Kim, et al., (11)
finding was
attributed to the different type of surgery and to
the different analgesic type that was used for
post operative analgesia. Kim, et al., performed
their study on patients undergoing thyroid
surgery and they used opioid based patient
controlled analgesia (PCA) for post operative
analgesia ,but the present study was performed
on
females
undergoing
laparoscopic
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gynecological surgery and the usage of
Diclofinac sodium as postoperative analgesia.
In the present study, it was found that,
hemodynamics (heart rate and mean arterial
pressure) values at various times of
measurements in group C, group P, group D
and group P/D were comparable. These results
were in agreement with Ghosh, et al. (15) who
reported that, there was no significant
difference in hemodynamic parameters, oxygen
saturation and ECG changes between
palonosetron/dexamethasone
group
and
palonosetron group in patients undergoing
laparoscopic cholecystectomy .In contrast Paul,
et al., (18) found that, there was significant
difference noted in mean heart rate between
palonsetron group and dexamethasone group in
patients undergoing ear and nose surgeries
under general anaesthesia .
The controversy between the present study
finding and, Paul,et al. (18) finding was
attributed to the premedication, the different
antiemetic administration time, the different
drugs which were used for anaesthesia and
different type of surgery. Paul, et al. used
midazolam for premedication, administered anti
emetic 5 minutes before induction, used
thiopental for induction and vecronium in
muscle relaxation and they performed their
study on patients who were scheduled for ear
and nose surgery. In the present study, no
premedication was given, anti emetic was given
immediately before induction, proprofol was
used for induction and rocronium for muscle
relaxation and this present study was performed
on female patients who were scheduled for
laparoscopic gynecological surgeries.
In this study, the incidences of the various
associated side-effects in the patients of group
P, group D and group P/D were minimal and
comparable. These detected findings were in
agreement with some workers. Kim, et al. (11)
reported that, the overall incidence of side
effects was low and didn’t significantly differ
among palonosetron group and palonosetron
/dexamethasone group in highly susceptible
thyroidectomy patients .Ghosh, et al. (15) found
that, none of the patient had any clinically
Aya A., et al
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serious side effects in patients undergoing
laparoscopic cholecystectomy. Tiwari et al.
(19) reported that, the incidence of adverse
effect in palonosteron group and palonosetron
/dexamethasone group was nill in patients
undergoing laparoscopic surgery under general
anaesthesia .
The limitations of the present study:
The anti emetics effects of the studied drugs
were not evaluated during the second 24 h
postoperatively. The population of the present
study was limited to ASA physical status class I
and ASA II adult females patients undergoing
laparoscopic surgery only. Only one dose of the
various tested drugs is evaluated.
CONCLUSION
Palonosetron (0.075 mg) alone is similar to
combined palonosetron (0.075mg) with
dexamethasone (8mg) in reducing the incidence
and severity of PONV. Both palonosetron alone
and combined palonosetron/dexamethason are
superior to dexamethasone (8mg) and in
reduction of the incidence, severity of PONV
with minimally associated side effects.
RECOMMENDATION
Palonosetron (0.075 mg) alone is recommended
for prevention of PONV in laparoscopic
surgeries.
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